Fluconazole is a new bis-triazole antifungal compound which has in vivo and in vitro activity against Candida spp. and Cryptococcus neoformans and excellent penetration into cerebrospinal fluid. However, little is known about the penetration of fluconazole into tissue sites other than cerebrospinal fluid. We therefore studied by high-pressure liquid chromatography the penetration of fluconazole into nine different tissue sites at times of peak and trough concentrations in plasma in rabbits. Fluconazole penetrated into all tissue sites. Tissue/plasma concentration ratios were greater at time of trough concentrations in plasma than at times of peak concentrations in plasma. The finding that fluconazole penetrated into target organs commonly infected by Candida spp. and C. neoformans further supports the therapeutic potential of fluconazole for disseminated candidiasis or cryptococcosis in immunocompromised hosts.
Fluconazole is a new bis-triazole antifungal compound which has in vivo and in vitro activity against Candida spp. and Cryptococcus neoformans (10) . Previous experimental and clinical studies demonstrated that fluconazole has excellent penetration into cerebrospinal fluid (1, 6, 8) , and early clinical observations indicated that fluconazole is effective in the treatment of cryptococcal meningitis (3, 4) . Little is known, however, about the penetration of fluconazole into tissue sites other than cerebrospinal fluid. A previous autoradiography study of mice injected with radiolabeled fluconazole demonstrated that activity appeared to be distributed throughout total body water (2) . This method, however, was semiquantitative and did not distinguish between the parent compound and possible metabolites. Since other tissues clearly are important sites of invasive candidiasis and cryptococcosis in immunocompromised patients (5, 9, 11, 13) , we studied the penetration of fluconazole into multiple tissues (lung, liver, spleen, kidney, choroid, vitreous humor, cerebrum, cerebellum, and skeletal muscle) of rabbits with a high-pressure liquid chromatography assay for fluconazole.
MATERIALS AND METHODS Antifungal drug. Fluconazole was kindly provided by Pfizer Central Research, Groton, Conn., as the parenteral formulation with a concentration of 1 mg of fluconazole per ml in 0.9% NaCl solution.
Animals. Adult female New Zealand White rabbits (Hazleton, Rockville, Md.) weighing between 2.5 and 3.5 kg were used in these studies. Rabbits were provided food and water ad lib, individually housed, and managed according to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 85-23, National Institutes of Health, Bethesda, Md.). Silastic central venous catheters were inserted under general anesthesia by a sterile surgical technique for repeated venous access as previously described (12) . Hepatic and renal toxicities were monitored by biochemical profiles of blood urea nitrogen, alkaline phosphatase, and serum glutamic oxalacetic transaminase (Smith-Kline Bio-Science Laboratories) obtained on the first and last days of administration of fluconazole. The second group consisted of three animals treated i.v. with 25 mg of fluconazole per kg per day for 14 days for the study of levels of fluconazole in tissue near times of peak concentrations in plasma. At 1 h after the final dose, animals were sacrificed with i.v. pentobarbital. Samples of plasma and sections of liver, spleen, lung, kidney, quadriceps, cerebrum, cerebellum, vitreous humor, and choroid were obtained immediately after euthanasia for the determination of concentrations of fluconazole in tissue near times of peak levels in plasma. Tissue was carefully dissected, with attention being directed toward avoiding contamination by blood. However, hemoglobin levels were not measured in tissue homogenates. Urine was drained from the urinary tract prior to dissection of the kidneys to avoid urinary contamination of renal tissue.
The third group of five rabbits received 25 mg of i.v. fluconazole per kg per day for 14 days for the study of fluconazole in tissue levels near times of trough concentrations in plasma. This group was sacrificed for the determination of concentrations in tissue when trough levels in plasma were reached, 24 h after the last dose. Plasma and tissue samples were frozen at -70°C until assayed for fluconazole.
Fluconazole assay. Plasma samples were assayed for fluconazole by high pressure liquid chromatography (6 amounts of fluconazole were used to establish standard curves. Preparations of control tissues were also examined to ensure that the extraction procedure did not produce peaks that would interfere with peaks of fluconazole or the internal standard.
Data analysis. For single-dose pharmacokinetics in plasma, the area under the plasma concentration-time curve was calculated by using the linear trapezoidal rule up to the final measured concentration and then extrapolating to infinity (7). The terminal half-life in the postdistributive phase was determined by regression analysis. The mean tissue/ plasma concentration ratio for each organ was calculated as the ratio between the mean concentrations of fluconazole in tissue and in plasma. The significance of differences between concentrations of fluconazole in different tissues was determined by Student's t test (unpaired).
RESULTS
Single-dose pharmacokinetics in plasma. The mean peak concentration of fluconazole in plasma in the first group was 29.3 ± 1.36 (standard error of the mean) pug/ml following a 5-min i.v. infusion. The mean terminal half-life was 8.85 ± 1.77 h, and the area under the concentration-time curve was 223 ± 31.9 ,ug. h/ml. The volume of distribution was 853 ± 29.9 mI/kg.
Tissue penetration studies. Fluconazole penetrated into all tissue sites at times of peak and trough concentrations in plasma ( Table 1) . Levels of fluconazole in tissue approximated those in plasma at the time of peak concentrations. The kidney had the highest mean tissue/plasma concentration ratio at the time of peak concentrations. Tissue/plasma concentration ratios at the time of trough concentrations were two to seven times the ratios obtained at the peak, indicating the persistence of fluconazole in tissue at low concentrations in plasma.
Concentrations of fluconazole were not significantly different among tissue sites at the time of peak concentrations in plasma. Concentrations of fluconazole at the time of trough concentrations in plasma, however, were significantly higher in the kidney and spleen than in the central nervous system (cerebrum, cerebellum, choroid, and vitreous humor 
